Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477763 · ClinicalTrials.gov registry record · Phase 4
Oasys vs. Extreme H20 Xtra 59
A Phase 4 study of Dry Eye, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT00477763: Completed Phase 4 study of Dry Eye, sponsored by Innovative Medical.
NCT00477763 is a Phase 4 study of Dry Eye that has completed, run by Innovative Medical. The registered enrollment target is 52 participants, below the 94-participant average among 41 other Dry Eye trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00477763, a Phase 4 study of Dry Eye, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare the performance of Oasys to Extreme H20 xtra 59 in dry eye contact lens pts who receive Restasis in 1 eye and vehicle (Endura) in the other eye.
Conditions Studied
Interventions
- DRUG Restasis, Refresh Endura
Study Locations (1)
Pennsylvania
- Hazleton Eye Specialists - Hazleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 4 |
What the finished NCT00477763 record still lists
NCT00477763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 94-participant average among 41 other Dry Eye trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which Restasis, Refresh Endura is the first listed.
NCT00477763 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00477763 about?
NCT00477763 is a clinical study titled "Oasys vs. Extreme H20 Xtra 59". To compare the performance of Oasys to Extreme H20 xtra 59 in dry eye contact lens pts who receive Restasis in 1 eye and vehicle (Endura) in the other eye.
What is the current status of trial NCT00477763?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2007-05. Estimated completion is 2008-02.
What conditions does trial NCT00477763 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT00477763?
The interventions under investigation include: Restasis, Refresh Endura (DRUG).
Who is sponsoring clinical trial NCT00477763?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00477763 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00477763's enrollment target sits among peer trials
52 20th of 41 higher than 22 of 41 other Dry Eye trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
Performance of Systane PRO Versus Refresh Optive Mega-3
RECRUITING · Phase 4
-
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia